亏损及盈利路径

港股IPO招股书披露先例 · 328 家公司,329 项

亏损及盈利路径类事项指申请人在往绩记录期间录得净亏损或经营亏损、乃至毛亏损的情形。招股书通常于概要、风险因素、业务及财务资料各章披露各期亏损金额、经调整亏损等计量、累计亏损,并解释成因,如研发投入巨大、股份支付、策略性定价、产能爬坡及成本上升等;申请人一般说明迈向收支平衡的路径与预期,包括收入增长、规模效应、成本优化等假设,董事往往申明业务可持续并附联席保荐人对其观点的确认。

2026-03-26Application Proof
广州极飞科技股份有限公司GUANGZHOU XAIRCRAFT TECHNOLOGY CO., LTD.

2023年净亏损1.328亿元后扭亏为盈

We were loss-making in 2023 and turned profitable starting from 2024, and recorded significant increase in net profit from 2024 to 2025.

Summary · 第 8 页

We recorded net profit of RMB70.4 million in 2024 as compared to net loss of RMB132.8 million in 2023, as a result of the substantial increase in our gross profit, primarily due to (i) increased sales of agricultural drones resulting from (a) enhanced customer satisfaction and growing interest of users and distributors driven by our continuous product innovation that improved product quality and delivered pricing advantages, (b) our business expansion in overseas markets, which broadened our customer base and sales reach, (ii) an increase in revenue contribution from our overseas sales with relatively higher gross profit margin, (iii) reduced hardware costs as we optimized the drone design through technical innovation to improve cost efficiency while maintaining performance stability, and (iv) increased sales of smart farm IoT products especially smart electric valves, driven by strong market demand, ongoing product innovation, exceptional cost efficiency and extensive sales channels.

Summary · 第 8 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-03-26Application Proof
四维智联(南京)科技股份有限公司AutoAI (Nanjing) Technology Co., Ltd.

往绩记录期间各年度均录得净亏损且亏损扩大

For the years ended December 31, 2023, 2024 and 2025, we had net losses of RMB265.3 million, RMB377.9 million, and RMB514.1 million, respectively, and adjusted net losses (a non-HKFRS measure) of RMB59.8 million, RMB132.7 million and RMB188.2 million, respectively.

Summary · 第 13 页

Our loss-making position during the Track Record Period was primarily attributable to the elevated technical demands and intricacies associated with the creation of smart cockpit solution.

Summary · 第 13 页

Our R&D expenses increased from RMB103.4 million in 2023 to RMB209.6 million in 2024 and to RMB268.1 million in 2025, accounting for 21.7%, 43.8% and 38.0% of our revenue in 2023, 2024 and 2025, respectively.

Business · 第 153 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-03-25Application Proof
陕西源杰半导体科技股份有限公司YUANJIE SEMICONDUCTOR TECHNOLOGY CO., LTD.

2024年录得净亏损610万元

In 2024, we recorded net loss of RMB6.1 million, primarily due to (i) a decrease in the overall gross profit margin of our telecommunications laser chip segment, because of the downward pricing pressure on certain products within this segment as a result of intensified market competition, and (ii) an increase in our research and development expenses and selling and marketing expenses to support our ongoing R&D activities and market expansion.

Summary · 第 12 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-03-23Prospectus
上海傅里叶半导体股份有限公司Shanghai FourSemi Semiconductor Co., Ltd.03625.HK

往绩记录期间各期均录得净亏损

In 2022, 2023, 2024 and the ten months ended October 31, 2024 and 2025, we incurred net loss of RMB65.9 million, RMB94.1 million, RMB56.8 million, RMB46.9 million and RMB51.8 million, respectively.

Summary · 第 12 页

Although we may continue to incur net losses in the short term, we are optimistic about achieving profitability through business scale expansion and operational efficiency improvements.

Business · 第 173 页

Achieving long-term profitability hinges on our continuous efforts to improve net profit margin, which we aim to accomplish through multiple strategic initiatives.

Business · 第 175 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-03-23Application Proof
深圳承泰科技股份有限公司Shenzhen Cheng-Tech Co., Ltd.

往绩记录期间各年均录得净亏损

We incurred net losses RMB96.6 million in 2023, which narrowed significantly to RMB21.8 million in 2024 and further to RMB5.8 million in 2025.

Business · 第 149 页

Our expectation to achieve and sustain profitability is based on reasonable assumptions, including: (i) continued increase in orders from customers, (ii) no material disruption to our production or delivery schedules, (iii) further improvement in unit economics driven by scale and product optimization, and (iv) no material adverse change in the macroeconomic, regulatory, or competitive environment.

Business · 第 150 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-03-20Application Proof
杭州新元素药业股份有限公司Atom Therapeutics Co., Ltd.

无产品收入且往绩期间录得亏损

Although we currently have no product approved for commercial sale and have not generated any revenue from product sales, we expect to commercialize one or more of our drug candidates over the coming years as they progress through late-stage development.

Financial Information · 第 246 页

In 2024 and 2025, our research and development expenses were RMB338.1 million and RMB179.7 million, respectively, accounting for 96.8% and 92.4% of our total operation expenses (representing research and development expenses and administrative expenses) for the same periods, respectively.

Financial Information · 第 246 页

During the Track Record Period and up to the Latest Practicable Date, we have primarily funded our working capital requirements through proceeds from equity financing.

Financial Information · 第 257 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-03-20Prospectus
杭州德适生物科技股份有限公司Hangzhou Diagens Biotechnology Co., Ltd.02526.HK

往绩记录期间净亏损主要源于研发开支

During the Track Record Period, our management did not consider net losses as an indication of the impairment for the non-financial assets mainly due to the factors that (i) we recorded net loss primarily caused by significant costs and expenses in relation to R&D which is consistent with our management’s expectations; (ii) our R&D were carried forward as planned during the Track Record Period; and (iii) the fair value of our principal business significantly exceeded the carrying amounts of our net assets based on our management’s assessment.

Financial Information · 第 236 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-03-20Prospectus
山东极视角科技股份有限公司Shandong Extreme Vision Technology Co., Ltd.06636.HK

往绩记录期间大部份年度录得净亏损

We recorded a loss of RMB60.7 million in 2022 and a loss of RMB56.2 million in 2023, primarily due to our cost structure and operating expenses associated with the expansion of our software-defined All-in-One AI solutions.

Summary · 第 9 页

We recorded a loss of RMB27.1 million in the nine months ended September 30, 2024 and a loss of RMB36.3 million in the nine months ended September 30, 2025, primarily due to increased operating expenses, including research and development expenses and administrative expenses, reflecting our continued investment in business expansion.

Summary · 第 9 页

However, we incurred net losses of RMB60.7 million, RMB56.2 million, and RMB36.3 million in 2022, 2023, and for the nine months ended September 30, 2025, respectively.

Business · 第 144 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-03-20Prospectus
广东华沿机器人股份有限公司Guangdong Huayan Robotics Co., Ltd.01021.HK

2022年及2025年录得净亏损

(Loss)/profit for the year/period | (83,366) | 1,895 | 17,869 | 9,037 | (15,588)

Summary · 第 9 页

We recorded loss for the year of approximately RMB29.9 million in 2025, primarily due to increases in listing expenses, share-based payment and R&D expenses.

Summary · 第 19 页

our revenue demonstrated steady growth, increasing by 24.6% from RMB310.4 million in 2024 to RMB386.9 million in 2025

Summary · 第 19 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-03-18Application Proof

往绩记录期间各年度均录得净亏损

We have incurred net losses during the Track Record Period, primarily due to (i) strategic investments in research and development to advance our technologies and in sales and marketing activities to attract and retain more customers and (ii) our business strategies which broadens the adoption of our solutions with flexible pricing models.

Summary · 第 7 页

Our historical loss-making position is attributable to several key factors: (i) heavy upfront investment in foundational technologies; (ii) strategic pricing to accelerate adoption and design-wins; and (iii) early-stage business lines with long-term monetization potential.

Summary · 第 9 页

In addition, with our growing installation volume and base of mass-production design-wins, we believe we are well positioned to transition toward sustainable profitability in the medium term.

Business · 第 155 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-03-17Application Proof
上海爱科百发生物医药技术股份有限公司Shanghai Ark Biopharmaceutical Co., Ltd.

往绩记录期间持续净亏损且预期扩大

As of the Latest Practicable Date, we did not have any commercialized products.

Summary · 第 15 页

As we continue to incur R&D expenses in relation to our R&D activities to develop our drug candidates and administrative expenses in relation to our daily operations, we expect to record an increase in net loss in 2025 compared to 2024.

Summary · 第 15 页

We expect to continue to incur significant expenses and operating losses in the future as we further the clinical development and/or pre-clinical studies of our product pipeline, expand our team and grow our business.

Financial Information · 第 251 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-03-16Application Proof

往绩记录期间持续净亏损

Our net loss was RMB546.0 million, RMB735.1 million and RMB991.1 million in 2023, 2024 and 2025, respectively.

Summary · 第 9 页

Our net losses primarily resulted from being in a ramp-up stage, with a strategic focus on long-term success and financial returns in the industrial AI agents market, rather than pursuing near-term profitability at the expense of future market potential.

Business · 第 139 页

While we have not yet achieved profitability, the combination of sustained revenue growth, improving gross profit margins and declining operating expense ratios supports our path toward breakeven and long-term profitability.

Business · 第 143 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-03-16Prospectus
江苏泽景汽车电子股份有限公司JIANGSU NEW VISION AUTOMOTIVE ELECTRONICS CO., LTD.02632.HK

往绩记录期间各期均录得净亏损

These strategic investments, while resulting in loss for the year/period of RMB256.1 million, RMB174.6 million, RMB137.9 million, RMB127.8 million and RMB343.7 million in 2022, 2023, 2024 and the nine months ended September 30, 2024 and 2025, respectively, have led to competitive advantages, fueling our rapid growth.

Summary · 第 18 页

In particular, we expect that our profitability will be enhanced in the next few years, primarily by (i) driving revenue growth; (ii) enhancing economies of scale; (iii) strengthening operating leverage; and

Summary · 第 18 页

(iv) optimizing working capital. With the industry’s growth trajectory aligning with our capacity to deliver cost-optimized solutions at mass scale, we are poised to transform early-stage investments into sustainable profitability, capturing value as the market matures.

Summary · 第 18 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-03-16Prospectus
浙江凯乐士科技集团股份有限公司Zhejiang Galaxis Technology Group Co., Ltd.02729.HK

往绩记录期间各年均录得净亏损

As we continued to expand our customer base and effectively improved our operating efficiency, our loss for the year narrowed from RMB209.6 million and RMB241.6 million in 2022 and 2023, to RMB178.1 million in 2024.

Summary · 第 12 页

While we have incurred losses during our growth phase, we believe we are well-positioned to achieve profitability through a combination of initiatives, including the following:

Summary · 第 12 页

We expect to achieve our gross margin improvement by implementing the following: (i) introduce technologically advanced products to create significant value for customers, which in turn enhances our pricing flexibility and drives our margin growth; (ii) enhance supply chain management through cost management of materials, implementation, manufacturing and labor and enhanced inventory management and procurement practices; and (iii) business mix optimization through capturing an increasing proportion of higher-margin after-sales services and single-function robot deployments, and pursuing targeted expansion into overseas markets.

Summary · 第 12 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-03-13Prospectus
国民技术股份有限公司NSING TECHNOLOGIES INC.02701.HK

往绩记录期间各期均录得净亏损

The combination of the above factors, namely industry fluctuations, price pressures, and sustained R&D investment, resulted in our operating losses.

Summary · 第 14 页

During the Track Record Period, although we experienced a 13.3% revenue decline in 2023 despite the sales growth of our chip and lithium-ion battery anode material products due to the impact of market demand and price, we recorded revenue growth since 2024 — our revenue increased by 12.6% in 2024 as compared with 2023, and increased by 16.7% in the nine months ended September 30, 2025 as compared with the same period in 2024.

Business · 第 129 页

Leveraging the above strategies and benefiting from positive market changes, the Company believes that it will be able to gradually improve profit margins and achieve net profit breakeven in the near future.

Summary · 第 14 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-02-27Application Proof

往绩记录期间持续录得净亏损

We incurred net losses during the Track Record Period.

Summary · 第 8 页

In 2023, 2024 and the nine months ended September 30, 2024 and 2025, we recorded losses of €4.7 million, €34.5 million, €28.3 million and €30.0 million, respectively.

Business · 第 128 页

Our adjusted result subsequently improved, from an adjusted net loss of €1.4 million in the nine months ended September 30, 2024 to an adjusted net profit of €1.2 million in the nine months ended September 30, 2025, reflecting the combined effect of revenue growth, gross margin expansion and improving cost efficiency.

Business · 第 128 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-02-27Application Proof
北京五和博澳药业股份有限公司Beijing Wehand-Bio Pharmaceutical Co., Ltd.

往绩记录期间录得净亏损

Our Directors are of the opinion that, taking into account the financial resources available to our Group, including revenue generated from sales of Sangbo'en, cash and cash equivalents, cash flows from financing activities, estimated net [REDACTED] from the [REDACTED] and cash burn rate, we have sufficient working capital to cover at least 125% of our costs, including general, administrative and operating costs (including any production costs) and research and development costs for at least the next 12 months from the date of this document.

Financial Information · 第 240 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-02-27Application Proof

2024年及2025年前九个月录得净亏损

As a result, we recorded profit and net profit margin in 2023 as compared to loss and net loss margin in 2024.

Business · 第 171 页

However, in 2025, FlareFlow business incurred relatively higher selling and marketing expenses to achieve rapid user base expansion. As a result, we recorded increased loss and net loss margin for the nine months ended September 30, 2025.

Business · 第 171 页

To achieve profitability, we aim to (1) focus on driving our revenue growth in untapped overseas micro drama market and cosmic market; (2) phase out businesses that have lower profit margins; (3) achieve higher production and distribution efficiency for our overseas micro dramas business; and (4) gain effective control of selling and marketing expenses for our overseas micro dramas business.

Business · 第 171 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-02-27Prospectus
南京埃斯顿自动化股份有限公司ESTUN AUTOMATION CO., LTD02715.HK

2024年录得净亏损8.177亿元

We recorded a loss for the year of RMB817.7 million in 2024, primarily due to a decline in gross profit resulting from decreased revenue and gross profit margin.

Business · 第 256 页

In the first nine months of 2025, our business gradually recovered from the temporary downturn in 2024.

Business · 第 258 页

We recorded net cash generated from operating activities of RMB300.1 million for the first nine months of 2025, as compared to net cash used in operating activities of RMB531.1 million in the same period of 2024, attributable to our net profit of RMB29.7 million for the nine months ended September 30, 2025 and our improved cash conversion cycle.

Business · 第 257 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-02-05Prospectus
北京海致科技集团股份有限公司Beijing Haizhi Technology Group Co., Ltd.02706.HK

往绩记录期间经营亏损及净亏损

Despite our loss from operations of RMB178.6 million and RMB202.3 million, respectively, in 2022 and 2023, we recorded profit from operations of RMB3.3 million in 2024.

Summary · 第 17 页

As a result of our forward-looking efforts to develop and commercialize our solutions, we incurred substantial costs in R&D, sales activities and internal management.

Business · 第 302 页

In particular, we expect to turn net loss to net profit in the next few years by (i) continuously scaling our business and expanding the applicable scenarios of our solutions; (ii) improving profitability; and (iii) refining our cash flow management and optimizing our working capital.

Business · 第 303 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看

Tell us